Cortisone (DB14681): A Comprehensive Monograph on its Pharmacology, Clinical Utility, and Historical Significance

Executive Summary

Cortisone is a foundational glucocorticoid hormone that has profoundly shaped modern medicine since its therapeutic potential was first realized in the mid-20th century. This report provides an exhaustive analysis of Cortisone, integrating its physicochemical properties, historical context, complex pharmacology, clinical applications, and evolving regulatory status. Identified chemically as a pregnene-based steroid, Cortisone functions as a biologically inactive prodrug, requiring hepatic conversion to its active metabolite, cortisol (hydrocortisone), to exert its effects. This activation is part of an elegant physiological system of tissue-specific hormone regulation that is co-opted for therapeutic purposes.

The pharmacological actions of Cortisone are mediated through both slow, genomic pathways and rapid, non-genomic mechanisms. The classic genomic pathway involves the binding of cortisol to intracellular glucocorticoid receptors, which then translocate to the nucleus to modulate the transcription of a wide array of genes, ultimately suppressing the synthesis of pro-inflammatory mediators and promoting anti-inflammatory signals. These effects are responsible for the drug's potent, broad-spectrum anti-inflammatory and immunosuppressive activities, which form the basis of its use in a vast range of conditions, including endocrine, rheumatic, allergic, and autoimmune disorders.

However, this potent efficacy is inextricably linked to a significant and predictable profile of adverse effects that mirrors its physiological actions when present in supraphysiologic concentrations. The safety profile, encompassing metabolic, musculoskeletal, cardiovascular, and immunologic toxicities, represents the primary limitation of its therapeutic use and necessitates careful risk-benefit assessment. The drug's pharmacokinetics are characterized by non-linear, dose-dependent behavior due to the saturable binding of its active metabolite to plasma proteins, a feature that explains the disproportionate increase in toxicity risk at higher doses.

Historically, the discovery of Cortisone's anti-inflammatory power was a landmark of translational medicine, earning its discoverers a Nobel Prize and heralding the age of steroid therapy. Today, its clinical role continues to evolve, with ongoing investigations in combination cancer therapies, while long-standing off-label uses, such as epidural injections, face increasing regulatory scrutiny due to severe safety concerns. Furthermore, recent research has uncovered a novel, non-canonical biological activity—its ability to act as a germinant for bacterial spores—which may open entirely new avenues for its therapeutic application beyond inflammation. Cortisone thus remains a molecule of immense clinical and scientific importance, serving as both a vital therapeutic tool and a compelling subject for ongoing research.

Identification and Physicochemical Properties of Cortisone

The precise identification of a pharmaceutical agent through its nomenclature and physicochemical characteristics is fundamental to its study, formulation, and regulatory oversight. Cortisone is a well-characterized small molecule with a rich history reflected in its various names and identifiers.

Nomenclature and Chemical Identifiers

Cortisone is known by a variety of systematic, generic, and historical names that trace its discovery and development.

• Generic Name: Cortisone.[1]
• Systematic (IUPAC) Name: The definitive chemical name is (8S,9S,10R,13S,14S,17R)-17-hydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-1,2,6,7,8,9,12,14,15,16-decahydrocyclopenta[a]phenanthrene-3,11-dione.[2]
• CAS Registry Number: 53-06-5.[3]
• DrugBank Accession Number: DB14681.[1]
• Synonyms and Historical Names: The extensive list of synonyms reflects the simultaneous discovery by independent research groups in the 1930s. Notable historical names include Kendall's Compound E, Reichstein's Substance Fa, and Wintersteiner's compound F.[2] Other common chemical synonyms include 17,21-Dihydroxypregn-4-ene-3,11,20-trione, 4-Pregnene-17α,21-diol-3,11,20-trione, and 11-Dehydro-17-hydroxycorticosterone.[2] Commercial and other names include Adrenalex and Cortone.[6]
• Other Database Identifiers: To facilitate cross-referencing across major biomedical databases, Cortisone is assigned identifiers such as PubChem CID: 222786, ChEBI ID: CHEBI:16962, and UNII: V27W9254FZ.[2]

The existence of multiple historical names, particularly those linked to researchers Kendall and Reichstein, is not merely a trivial detail of nomenclature. It is a direct reflection of the intense, competitive, and parallel scientific environment of the mid-20th century, where multiple laboratories were racing to isolate and characterize the hormones of the adrenal cortex. This illustrates the concept of "multiples" in scientific discovery, where breakthroughs are often achieved nearly simultaneously by independent teams, underscoring the nature of scientific progress itself.

Structural and Physical Characteristics

Cortisone's biological activity and pharmacokinetic profile are direct consequences of its specific chemical structure and physical properties. It is classified as a C21-steroid, meaning it is built upon a 21-carbon skeleton derived from pregnane.[2] Its structure is characterized by a cyclopentenoperhydrophenanthrene nucleus, with key functional groups dictating its function: hydroxy groups at positions C-17 and C-21, and oxo (ketone) groups at positions C-3, C-11, and C-20.[2] The 11-oxo group is particularly significant, as its reduction to a hydroxyl group is the metabolic step that activates the molecule.

The key physicochemical and structural identifiers are consolidated in Table 1.

Table 1: Physicochemical and Structural Identifiers of Cortisone

Property	Value	Source(s)
Molecular Formula	$C_{21}H_{28}O_5$	2
Molecular Weight	360.44 - 360.45 g/mol	3
Physical Appearance	White to almost white powder or crystal	4
Melting Point	220 - 224 °C	6
Solubility	DMF: 20 mg/ml; DMSO: 20 mg/ml; DMSO:PBS (pH 7.2) (1:2): 0.3 mg/ml	3
InChI Key	MFYSYFVPBJMHGN-ZPOLXVRWSA-N	3
SMILES String	[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)CC(=O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C	10

The molecule's lipophilic nature, evidenced by its solubility in organic solvents like DMSO and its limited aqueous solubility, is crucial for its ability to passively diffuse across cell membranes to reach its intracellular glucocorticoid receptor, a necessary step for its primary mechanism of action.[3] Definitive identification for quality control and research purposes relies on analytical techniques such as Liquid Chromatography-Mass Spectrometry (LC-MS/MS) and Nuclear Magnetic Resonance (NMR) spectroscopy.[11]

Historical Context and Discovery

The emergence of Cortisone as a therapeutic agent is a landmark story in medical history, representing a powerful synergy between fundamental biochemistry, astute clinical observation, and industrial chemistry.

The Isolation of "Compound E"

The journey began in the 1930s with efforts to understand the complex hormonal milieu of the adrenal cortex. Between 1935 and 1936, two independent groups—one led by Edward Calvin Kendall and Harold L. Mason at the Mayo Clinic in the United States, and the other by Tadeus Reichstein in Switzerland—successfully isolated a series of structurally related steroids from large quantities of bovine adrenal glands.[8] Among these was a substance Kendall designated "Compound E," which Reichstein called "Substance Fa".[2] Early experiments showed that crude adrenal extracts could sustain life and improve muscle strength in adrenalectomized animals, confirming their vital physiological role, but the specific anti-inflammatory potential of Compound E remained unknown.[13]

From Laboratory Synthesis to a "Wonder Drug"

The transition from a rare biological isolate to a viable therapeutic was contingent on chemical synthesis. In 1946, Louis Sarett, a chemist at Merck Research Labs, achieved the first total synthesis of Compound E, a monumental achievement that paved the way for producing the quantities needed for clinical trials.[13]

This scientific capability converged with a pressing clinical need, championed by rheumatologist Philip Hench, a colleague of Kendall's at the Mayo Clinic. For years, Hench had meticulously observed that the debilitating symptoms of his rheumatoid arthritis patients often went into spontaneous remission during episodes of jaundice or pregnancy.[14] This led him to hypothesize the existence of an endogenous anti-inflammatory substance, which he termed "antirheumatic substance X".[14] Convinced that this factor might be an adrenal hormone present in both sexes, he persuaded a reluctant Kendall to provide him with a small amount of the newly synthesized Compound E.[14]

In September 1948, the first dose was administered to a patient with severe, crippling rheumatoid arthritis. The results were immediate and dramatic, with a profound reduction in inflammation and restoration of mobility.[13] This successful experiment, a quintessential example of bench-to-bedside translational medicine, was a watershed moment. The news of this "wonder drug" spread rapidly, and by 1950, the compound was officially named "cortisone".[13] In recognition of their transformative work on adrenal cortex hormones, Kendall, Hench, and Reichstein were jointly awarded the 1950 Nobel Prize in Physiology or Medicine.[8] Commercial production was scaled up by Merck & Co., with subsequent process improvements by chemists like Percy Julian making the synthesis more efficient and safer.[8]

However, the initial euphoria was soon tempered by a more critical scientific appraisal. A 1954 British trial conducted by the Medical Research Council directly compared the efficacy of cortisone against high-dose aspirin for rheumatoid arthritis and concluded that there was no significant difference in outcomes between the two treatments.[14] This finding, which deeply offended Hench and his American colleagues, was more than a mere scientific disagreement. It represented a seminal moment in the history of clinical trial methodology, marking a shift away from celebrating dramatic but potentially short-lived effects toward a more sober, evidence-based assessment that weighs long-term benefits and risks against existing standards of care. This event signaled the end of Cortisone's "honeymoon" period and the beginning of the ongoing clinical challenge: how to harness its immense power while mitigating its considerable risks.

Comprehensive Pharmacology

The pharmacological profile of Cortisone is complex, defined by its nature as a prodrug and its ability to modulate cellular function through multiple distinct mechanisms operating on different timescales.

Pharmacodynamics: A Dual Mechanism of Action

The pharmacodynamic effects of Cortisone—what the drug does to the body—are entirely dependent on its conversion to the active hormone cortisol.

The Prodrug Concept: Conversion to Active Cortisol

Cortisone itself is a biologically inert molecule.[1] Its therapeutic activity is contingent upon its metabolic activation to cortisol (also known as hydrocortisone). This conversion is catalyzed by the enzyme 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1), which stereospecifically reduces the ketone group at carbon 11 to a hydroxyl group.[3] This activation step occurs predominantly in the liver, making it the primary site of cortisol generation following systemic administration of Cortisone.[8]

This activation is one half of a sophisticated physiological "shunt" system that regulates glucocorticoid activity at the tissue level. The reverse reaction, the inactivation of active cortisol back to inert Cortisone, is catalyzed by a different isozyme, 11β-hydroxysteroid dehydrogenase type 2 (11β-HSD2).[8] This enzyme is highly expressed in mineralocorticoid-sensitive tissues, most notably the kidneys. Its function there is critical: by rapidly inactivating cortisol, it prevents it from binding to and activating mineralocorticoid receptors, which have a high affinity for cortisol. This protective mechanism is essential for maintaining normal electrolyte balance and blood pressure.[8] The administration of Cortisone as a prodrug cleverly leverages this natural regulatory system, allowing for systemic activation in the liver while benefiting from peripheral inactivation in key tissues to minimize unwanted mineralocorticoid side effects.

Genomic Effects via Glucocorticoid Receptor Modulation

The best-understood and primary mechanism of corticosteroid action is genomic, involving the regulation of gene transcription. This pathway is responsible for the majority of the sustained anti-inflammatory and immunosuppressive effects but requires hours to days to fully manifest.[16]

1. Receptor Binding: Active cortisol, being lipophilic, readily diffuses across the cell membrane into the cytoplasm. There, it binds to its specific intracellular receptor, the glucocorticoid receptor (GR), which is held in an inactive state by chaperone proteins.[15]
2. Nuclear Translocation: Ligand binding induces a conformational change in the GR, causing it to dissociate from the chaperone proteins and translocate into the cell nucleus.[15]
3. Gene Regulation: Once in the nucleus, the cortisol-GR complex modulates gene expression through two main processes:

• Transrepression: The complex directly or indirectly interacts with and inhibits the activity of pro-inflammatory transcription factors, most notably Nuclear Factor-kappa B (NF-κB) and Activator Protein-1 (AP-1).[16] By preventing these factors from binding to DNA, the cortisol-GR complex effectively shuts down the transcription of genes encoding a wide array of inflammatory mediators, including cytokines (e.g., interleukins, TNF-α), chemokines, cell adhesion molecules, and key inflammatory enzymes like phospholipase A2 (PLA2) and cyclooxygenase-2 (COX-2).[16]
• Transactivation: The complex can also bind directly to specific DNA sequences known as glucocorticoid response elements (GREs) in the promoter regions of target genes. This promotes the transcription of genes with anti-inflammatory properties, such as annexin A1 (lipocortin-1) and interleukin-10 (IL-10).[9]

The net result of these genomic actions is a powerful and broad-spectrum suppression of the inflammatory and immune responses.

Rapid Non-Genomic Effects

In addition to the slower genomic pathway, corticosteroids can elicit biological effects within seconds to minutes. These rapid actions are too swift to be mediated by changes in gene expression and are termed non-genomic.[15] While the exact mechanisms are still under investigation, they are thought to involve:

• Interactions with membrane-bound forms of the GR.
• Direct modulation of intracellular signaling cascades through cytosolic GR.
• Nonspecific physicochemical interactions with cellular membranes.

These rapid effects are clinically significant and are believed to contribute to the immediate benefits of high-dose corticosteroid therapy in acute conditions. Key non-genomic actions include the rapid inhibition of PLA2, which reduces the release of arachidonic acid (the precursor to prostaglandins and leukotrienes), and the stabilization of mast cell and lysosomal membranes, preventing the release of inflammatory mediators.[9]

This dual-speed mechanism of action provides a compelling explanation for the broad clinical utility of corticosteroids. The rapid, non-genomic effects are crucial for managing acute, life-threatening inflammatory events such as anaphylactic shock or severe asthma attacks, where immediate reduction of vascular permeability and bronchoconstriction is paramount. In contrast, the slower, sustained genomic effects are responsible for controlling the underlying inflammation in chronic autoimmune and inflammatory diseases like rheumatoid arthritis and lupus. Few other drug classes possess this capacity for both immediate rescue and long-term disease modification, securing the enduring role of corticosteroids in the therapeutic armamentarium.

The relative potency of different corticosteroids varies, which is a critical consideration in clinical practice. Table 2 provides a comparison of common corticosteroids.

Table 2: Relative Potency of Common Corticosteroids

Drug Name	Approximate Equivalent Dose (mg)	Relative Glucocorticoid (Anti-inflammatory) Activity	Relative Mineralocorticoid (Salt-retaining) Activity	Biological Half-life
Cortisone	25	0.8	0.8	Short (8-12 hours)
Hydrocortisone (Cortisol)	20	1	1	Short (8-12 hours)
Prednisolone	5	4	0.5	Intermediate (12-36 hours)
Dexamethasone	0.75	30	0	Long (36-72 hours)
(Data compiled from 21)

This table is an essential clinical tool, allowing for the calculation of equivalent doses when switching between agents. It clearly illustrates that while Cortisone is less potent than its synthetic derivatives, its significant mineralocorticoid activity must be considered. Conversely, dexamethasone offers potent anti-inflammatory effects with virtually no salt retention, making it suitable for conditions where fluid balance is a concern, such as in the management of cerebral edema.

Pharmacokinetics: Absorption, Distribution, Metabolism, and Excretion (ADME)

The pharmacokinetic profile of Cortisone determines its concentration and persistence at the site of action, influencing both its efficacy and toxicity.

Absorption and Bioavailability

Following oral administration, corticosteroids like Cortisone are generally well and rapidly absorbed from the gastrointestinal tract, with peak plasma concentrations typically achieved within 1 to 3 hours.[23] The oral bioavailability of closely related steroids like prednisone and prednisolone is high, ranging from 80% to 100%, suggesting efficient absorption for Cortisone as well.[24]

Plasma Protein Binding and Distribution

The distribution of the active metabolite, cortisol, is heavily influenced by its extensive binding to plasma proteins. This binding is a critical determinant of the drug's pharmacokinetic behavior.[9]

• Binding Proteins: Cortisol binds to two main proteins in the plasma:

1. Corticosteroid-Binding Globulin (CBG, or transcortin): Binds cortisol with high affinity but has a low binding capacity.
2. Albumin: Binds cortisol with low affinity but has a very high binding capacity.[24]

• Non-Linear Pharmacokinetics: This dual-binding system results in non-linear, dose-dependent pharmacokinetics. At low physiological or therapeutic concentrations, the majority of cortisol (~70%) is bound to high-affinity CBG.[25] However, the binding capacity of CBG becomes saturated at the higher plasma concentrations achieved with moderate to high therapeutic doses (e.g., >20 mg prednisolone equivalent).[24] Once CBG is saturated, any further increase in the total drug concentration leads to a disproportionate rise in the concentration of albumin-bound and, most importantly, free (unbound) cortisol.
• The Active Fraction: Only the free fraction of the drug is pharmacologically active, as it is the only form that can diffuse across cell membranes to interact with the GR.[25] The non-linear increase in this active fraction at higher doses is a key pharmacological principle. It explains why both the therapeutic effects and, more notably, the adverse effects of corticosteroids escalate dramatically and non-linearly as the dose is increased. This also implies that patients with conditions that lower plasma protein levels, such as hypoalbuminemia in liver disease, will have a higher free fraction of the drug at any given dose, placing them at an increased risk of toxicity.[23]

Hepatic Metabolism and Elimination Pathways

The elimination of corticosteroids from the body is primarily handled by the liver.

• Metabolism: Cortisol undergoes extensive hepatic metabolism, mainly through reduction of its steroid ring structure to form inactive metabolites like dihydrocortisol and tetrahydrocortisol.[25] These metabolites are then conjugated, typically with glucuronic acid or sulfate, to form water-soluble compounds that can be easily excreted.[25]
• Half-Life: The plasma half-life of cortisol is relatively short, approximately 60 to 90 minutes.[21] However, this value can be misleading from a clinical perspective. The biological half-life—the duration of its physiological effects—is considerably longer (8-12 hours for Cortisone/cortisol).[21] This discrepancy arises because the genomic effects of the drug persist long after the drug has been cleared from the plasma, as the newly synthesized proteins and repressed inflammatory mediators take time to turn over.
• Excretion: The water-soluble conjugated metabolites are eliminated from the body primarily via renal excretion in the urine.[16] Over 90% of a secreted dose of glucocorticoid is ultimately excreted through this pathway.[25]

Clinical Applications and Therapeutic Efficacy

Leveraging its potent anti-inflammatory and immunosuppressive properties, Cortisone and its corticosteroid analogues are employed in the management of a remarkably diverse array of medical conditions.

Approved Therapeutic Indications

The therapeutic applications of corticosteroids span nearly every field of medicine. They are indicated for disorders characterized by aberrant or excessive inflammation and immune responses. Key indications include:

• Endocrine Disorders: As physiologic replacement therapy for primary adrenal insufficiency (Addison's disease) and congenital adrenal hyperplasia, where the body's endogenous cortisol production is deficient.[1]
• Rheumatic and Musculoskeletal Disorders: To control inflammation and symptoms in rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, acute gouty arthritis, and inflammatory conditions of soft tissues like bursitis and tendinitis.[27]
• Collagen Vascular and Autoimmune Diseases: For the management of systemic lupus erythematosus (SLE) and systemic dermatomyositis (polymyositis).[27]
• Dermatologic Diseases: For severe inflammatory skin conditions such as pemphigus, severe forms of eczema and psoriasis, and severe contact dermatitis.[8]
• Allergic Conditions: To treat severe or incapacitating allergic states, including bronchial asthma, allergic rhinitis (hay fever), drug hypersensitivity reactions, and urticaria.[27]
• Ophthalmic Diseases: For allergic and inflammatory conditions of the eye, such as allergic conjunctivitis and chorioretinitis.[16]
• Respiratory Diseases: In the management of symptomatic sarcoidosis and aspiration pneumonitis.[16]
• Hematologic and Neoplastic Disorders: For acquired (autoimmune) hemolytic anemia and as a component of palliative chemotherapy regimens for leukemias and lymphomas.[16]
• Gastrointestinal Diseases: To induce remission in inflammatory bowel diseases like ulcerative colitis and Crohn's disease.[16]

Dosing Regimens and Administration

Corticosteroid dosing is highly individualized based on the specific condition, its severity, and the patient's response. A critical distinction is made between physiologic and pharmacologic dosing.

• Physiologic Replacement Dosing: This involves using low doses intended to replicate the body's normal daily cortisol production (approximately 5 mg of prednisone equivalent). For Cortisone, this typically translates to 25-35 mg per day, often divided to mimic the natural circadian rhythm of cortisol secretion.[22]
• Pharmacologic (Anti-inflammatory/Immunosuppressive) Dosing: This requires supra-physiologic doses that can range widely, from 25 mg to 300 mg of Cortisone per day, depending on the therapeutic goal.[26] The principle is to use the lowest effective dose for the shortest possible duration to minimize adverse effects.
• Routes of Administration: While oral tablets are the most common form for systemic therapy, corticosteroids are available in a multitude of formulations to allow for targeted delivery and minimize systemic exposure. These include intravenous (IV) and intramuscular (IM) injections for rapid or systemic effects, topical creams and ointments for skin conditions, and inhaled formulations for respiratory diseases like asthma.[22]

Off-Label and Investigational Uses in Modern Medicine

Despite being one of the oldest classes of modern drugs, the clinical role of corticosteroids continues to be refined and investigated.

• Investigational Uses in Clinical Trials: Cortisone and its analogues remain active components of modern clinical research, often as part of combination therapies.
• Oncology: A recruiting Phase 1b clinical trial (NCT06251180) is evaluating the combination of a novel agent, Rocbrutinib, with the standard R-CHOP chemotherapy regimen (which includes a corticosteroid like prednisone) for B-cell Non-Hodgkin Lymphoma.[32] This highlights the evolving role of corticosteroids as crucial adjuncts that leverage their lymphocytopenic and anti-inflammatory effects to enhance the efficacy of other cancer treatments.
• Orthopedics and Surgery: Completed trials have explored the use of Cortisone to manage post-surgical inflammation following hip arthroscopy (NCT06082271) and as a comparator against regenerative therapies like stem cell injections for partial rotator cuff tears (NCT02918136).[33]
• Common Off-Label Uses:
• Epidural Injections for Pain: For decades, corticosteroids have been widely used via epidural injection to treat neck and back pain. This use is off-label, and its efficacy and safety have not been formally established. In recent years, this practice has come under intense regulatory scrutiny due to reports of rare but catastrophic neurologic adverse events, including stroke, paralysis, and death, leading the U.S. FDA to issue a stern warning against this application.[35]
• Neuropathic Pain: The use of steroids to treat nerve pain, such as sciatica, is also considered an off-label application.[31]
• COVID-19: During the pandemic, corticosteroids like hydrocortisone and dexamethasone became a standard of care for managing the severe inflammatory response (cytokine storm) in hospitalized patients with serious COVID-19 complications.[37]

The current landscape of Cortisone's use presents a fascinating juxtaposition. On one hand, it is being integrated into cutting-edge clinical trials for complex diseases like cancer, demonstrating its continued relevance. On the other hand, a long-standing and common off-label practice (epidural injection) is being strongly discouraged by regulatory bodies due to a re-evaluation of its risk-benefit profile. This dynamic encapsulates a major theme in modern pharmacology: the imperative to apply rigorous, evidence-based standards of safety and efficacy to all medical practices, including those that have been established for decades, leading to a continual refinement of a drug's appropriate clinical role.

Safety Profile and Risk Management

The profound therapeutic benefits of Cortisone are counterbalanced by a formidable and extensive profile of potential adverse effects. These effects are not idiosyncratic but are predictable extensions of the drug's glucocorticoid and mineralocorticoid actions, becoming more prevalent and severe with higher doses and longer durations of therapy.

Adverse Effects: Short-Term and Long-Term Consequences

The toxicities of corticosteroid therapy can be categorized by their typical onset and the organ systems they affect.

• Acute and Short-Term Adverse Effects (Days to Weeks):
• Neuropsychiatric: Insomnia, mood swings, irritability, anxiety, and in some cases, acute psychosis or delirium.[28]
• Metabolic: Hyperglycemia due to increased gluconeogenesis and insulin resistance, which can unmask latent diabetes or worsen glycemic control in existing diabetics.[38]
• Fluid and Electrolyte: Sodium and fluid retention, leading to peripheral edema and potential exacerbation of hypertension or heart failure. Hypokalemia can also occur.[1]
• Gastrointestinal: Gastric irritation, dyspepsia, and an increased risk of peptic ulceration, particularly when co-administered with NSAIDs.[28]
• General: Increased appetite and subsequent weight gain.[28]
• Chronic and Long-Term Adverse Effects (Months to Years):
• Endocrine and Metabolic: Development of iatrogenic Cushing's syndrome, characterized by central obesity, a "moon face," a dorsocervical fat pad ("buffalo hump"), and purple striae.[17] A critical long-term consequence is hypothalamic-pituitary-adrenal (HPA) axis suppression, where the body's own production of cortisol is shut down. Abrupt cessation of the drug can lead to a life-threatening adrenal crisis.[16]
• Musculoskeletal: Osteoporosis is a major concern, resulting from decreased calcium absorption and inhibited osteoblast function, leading to a significantly increased risk of fractures.[17] Avascular necrosis (osteonecrosis), particularly of the femoral head, and steroid-induced myopathy (proximal muscle weakness) are also serious complications.[17]
• Immunologic: Chronic immunosuppression increases susceptibility to a wide range of bacterial, viral, fungal, and opportunistic infections. Wound healing is often impaired.[38]
• Ophthalmic: Increased risk of developing posterior subcapsular cataracts and glaucoma.[16]
• Dermatologic: Skin atrophy (thinning), easy bruising, telangiectasias, acne, and impaired wound healing.[28]
• Cardiovascular: Sustained hypertension and dyslipidemia.[16]

Table 3: Summary of Common and Severe Adverse Effects of Cortisone

Organ System	Acute / Short-Term Effects	Chronic / Long-Term Effects
Neuropsychiatric	Insomnia, mood lability, anxiety, psychosis	Depression, cognitive changes
Endocrine/Metabolic	Hyperglycemia, increased appetite, fluid retention	Cushing's syndrome, HPA axis suppression, diabetes mellitus
Musculoskeletal	-	Osteoporosis, fractures, avascular necrosis, myopathy
Cardiovascular	Hypertension, hypokalemia	Sustained hypertension, dyslipidemia
Gastrointestinal	Gastric irritation, dyspepsia	Peptic ulcer disease, pancreatitis
Immunologic	-	Increased susceptibility to infection, impaired wound healing
Dermatologic	Facial flushing, increased sweating	Skin atrophy, striae, easy bruising, acne
Ophthalmic	Increased intraocular pressure	Cataracts, glaucoma

Contraindications, Warnings, and Precautions

Given the extensive side effect profile, the use of Cortisone is contraindicated or requires extreme caution in several clinical situations.

• Absolute Contraindications:
• Systemic fungal infections, as immunosuppression can lead to disseminated, life-threatening disease.[46]
• Known hypersensitivity to Cortisone or any component of its formulation.[46]
• Administration of live or live-attenuated vaccines in patients receiving immunosuppressive doses of corticosteroids, due to the risk of vaccine-induced illness.[26]
• Warnings and Precautions (Relative Contraindications): Corticosteroids should be used with caution in patients with:
• Infections: Active or latent infections such as tuberculosis or ocular herpes simplex, as steroids can mask signs of infection and exacerbate the condition.[45]
• Cardiovascular Disease: Congestive heart failure, recent myocardial infarction, and hypertension, due to the risk of fluid retention and electrolyte disturbances.[45]
• Gastrointestinal Disorders: Active peptic ulcer disease, diverticulitis, or recent intestinal anastomoses, due to increased risk of perforation and bleeding.[45]
• Endocrine Disorders: Diabetes mellitus (requires closer glucose monitoring) and osteoporosis (risk of worsening bone density).[28]
• Psychiatric Conditions: A history of psychosis or severe mood disorders, which can be exacerbated by steroid therapy.[48]
• Special Alerts: The U.S. FDA has issued a specific and serious warning regarding the unapproved use of injectable corticosteroids for epidural administration, highlighting the risk of severe neurologic events including paralysis, stroke, and death.[35]

Use in Special Populations

• Pregnancy and Lactation: Corticosteroids should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. An effective form of birth control is recommended for patients of childbearing potential.[30]
• Pediatric Use: Chronic use of corticosteroids can lead to growth suppression in children. Growth and development should be carefully monitored.[38]
• Geriatric Use: Elderly patients may be more susceptible to adverse effects like osteoporosis and hypertension due to pre-existing comorbidities and age-related physiological changes.[49]

Significant Drug Interactions

The clinical use of Cortisone is complicated by a large number of potential drug interactions, which can alter its efficacy or increase its toxicity. These interactions can be broadly categorized as either pharmacodynamic or pharmacokinetic.

Table 4: Clinically Significant Drug Interactions with Cortisone

Interacting Drug/Class	Example(s)	Mechanism of Interaction	Clinical Recommendation and Consequence
CYP3A4 Inducers	Rifampin, Carbamazepine, Phenytoin, Phenobarbital	Increased hepatic metabolism of corticosteroids via induction of the CYP3A4 enzyme.	Avoid or Use Alternate Drug/Monitor Closely. Decreased corticosteroid levels, leading to reduced therapeutic efficacy. Dose increase may be needed. 26
CYP3A4 Inhibitors	Ketoconazole, Clarithromycin, Ritonavir	Decreased hepatic metabolism of corticosteroids via inhibition of the CYP3A4 enzyme.	Avoid or Use Alternate Drug/Monitor Closely. Increased corticosteroid levels, leading to a higher risk of systemic adverse effects and toxicity. 1
Live/Live-Attenuated Vaccines	Measles, Mumps, Rubella (MMR), Varicella, BCG	Pharmacodynamic antagonism: Corticosteroid-induced immunosuppression impairs the ability to mount an immune response and increases the risk of disseminated infection from the vaccine virus/bacterium.	Contraindicated. Avoid administration of live vaccines during and for at least 3 months after immunosuppressive corticosteroid therapy. 26
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)	Aspirin, Ibuprofen, Naproxen	Pharmacodynamic synergism: Both drug classes can cause gastrointestinal irritation.	Monitor Closely. Increased risk of developing peptic ulcers and gastrointestinal bleeding. 1
Potassium-Depleting Diuretics	Furosemide, Hydrochlorothiazide	Pharmacodynamic synergism: Both corticosteroids (via mineralocorticoid effect) and these diuretics promote renal potassium excretion.	Monitor Closely. Increased risk of severe hypokalemia, which can lead to cardiac arrhythmias. 1
Anticoagulants	Warfarin	Complex pharmacodynamic interaction: Corticosteroids can increase blood coagulability or impair vascular integrity.	Monitor Closely. Unpredictable effects on anticoagulation. Frequent monitoring of INR is required. 51
Oral Hypoglycemic Agents / Insulin	Glipizide, Metformin, Insulin	Pharmacodynamic antagonism: Corticosteroids increase blood glucose levels.	Monitor Closely. Decreased efficacy of anti-diabetic medications. Dose adjustments are often necessary to maintain glycemic control. 1
Antacids	Aluminum hydroxide, Bismuth subnitrate	Decreased gastrointestinal absorption of oral corticosteroids.	Administer Separately. Reduced bioavailability of Cortisone. Doses should be separated by several hours. 1

Pharmacodynamic Interactions

These interactions occur when two drugs have additive, synergistic, or antagonistic effects at the site of action.

• Vaccines: Corticosteroids suppress the immune system, which can severely blunt the protective response to both live and inactivated vaccines. The administration of live vaccines to an immunosuppressed patient is particularly dangerous and generally contraindicated.[26]
• NSAIDs: The combination of corticosteroids and NSAIDs significantly increases the risk of gastrointestinal toxicity, including gastritis and peptic ulcer disease.[1]
• Diuretics: When used with potassium-depleting diuretics, corticosteroids can exacerbate potassium loss, leading to clinically significant hypokalemia.[1]

Pharmacokinetic Interactions

These interactions occur when one drug alters the absorption, distribution, metabolism, or excretion of another. For Cortisone, the most significant interactions involve the cytochrome P450 3A4 (CYP3A4) enzyme system in the liver.

• CYP3A4 Inducers: Potent inducers of CYP3A4, such as the anticonvulsants carbamazepine and phenytoin, and the antibiotic rifampin, can accelerate the metabolism of corticosteroids. This leads to lower plasma concentrations and a potential loss of therapeutic effect, often requiring a dose increase of the steroid.[23]
• CYP3A4 Inhibitors: Strong inhibitors of CYP3A4, such as the antifungal ketoconazole and the macrolide antibiotic clarithromycin, can impair the metabolism of corticosteroids. This results in elevated plasma concentrations and a heightened risk of developing dose-related adverse effects.[26]
• Bioavailability Modifiers: Certain substances, like antacids containing aluminum or bismuth, can bind to Cortisone in the gut and reduce its oral absorption and overall bioavailability.[1]

Regulatory Status, Formulations, and Brand Names

The regulatory status and availability of Cortisone vary globally, reflecting different national healthcare systems and regulatory assessments.

Regulatory Landscape: FDA and TGA Perspectives

• United States - Food and Drug Administration (FDA): Cortisone acetate was originally approved under the brand name CORTONE. However, the holder of the New Drug Application later requested its withdrawal from the market for reasons of business strategy, not due to safety or efficacy concerns. This determination allows for the continued approval of generic versions.[52] The most significant recent regulatory action concerning the corticosteroid class is the FDA's 2014 safety warning regarding the serious neurologic risks associated with the off-label epidural injection of these drugs.[35]
• Australia - Therapeutic Goods Administration (TGA) and Pharmaceutical Benefits Scheme (PBS):
• In Australia, Cortisone is available by prescription as cortisone acetate tablets under the brand name Cortate.[53] It is subsidized under the PBS as a "Restricted Benefit," meaning it is intended for specific therapeutic uses.[54]
• Hydrocortisone, the active metabolite, is also widely available and approved by the TGA for a broad range of indications. Injectable hydrocortisone sodium succinate is marketed under brand names such as HYDROCORTISONE PANPHARMA and Solu-Cortef and is also listed on the PBS.[27]
• Topical hydrocortisone preparations are available both over-the-counter and by prescription, with brand names like APOHEALTH Hydrocortisone 1% Cream.[57]
• Global Regulatory Trends: There is an increasing global trend towards tighter regulation of corticosteroids. For instance, regulatory bodies in countries like the Philippines are reclassifying topical corticosteroids from over-the-counter (OTC) to prescription-only status. This move is driven by growing concerns over misuse, abuse, and the emergence of conditions like Topical Steroid Withdrawal (TSW) syndrome, which can result from the prolonged and inappropriate use of these potent agents.[58]

Commercially Available Formulations and Brand Names

Corticosteroids are formulated in a wide variety of dosage forms to suit different clinical needs, from systemic therapy to localized treatment.

• Systemic Formulations:
• Oral Tablets: The most common formulation for Cortisone itself, available in strengths of 5 mg, 10 mg, and 25 mg.[26]
• Injectables: Intramuscular (IM) and intravenous (IV) preparations are available, typically using a more water-soluble salt like hydrocortisone sodium succinate for parenteral administration.[22]
• Local Formulations (for the corticosteroid class):
• Topical: Creams, ointments, lotions, and solutions for dermatologic conditions.[28]
• Inhaled: Aerosols and dry powders for asthma and COPD.[22]
• Intranasal: Sprays for allergic rhinitis.[30]
• Ophthalmic: Drops and ointments for eye inflammation.[28]
• Intra-articular: Injections directly into joints.[8]
• Brand Names:
• Cortisone: Cortone (US), Cortate (Australia).[7]
• Hydrocortisone (Cortisol): Cortef, Solu-Cortef (US/Australia), Hydrocort, Hysone (Australia).[7]
• Prednisone: Deltalone, Prednicot (US).[7]
• Prednisolone: Orapred (US), Panafcortelone, Predsone, Solone (Australia).[7]
• Dexamethasone: Decadron (US).[7]

Synthesis and Expert Analysis

After more than seven decades of clinical use, Cortisone remains a cornerstone of pharmacotherapy, yet its place in medicine is defined by a fundamental duality. It is both an indispensable tool for controlling inflammation and a potent source of iatrogenic disease. A comprehensive analysis reveals not only this central dilemma but also surprising new biological roles that may define its future.

Balancing Efficacy and Toxicity: The Corticosteroid Dilemma

Cortisone is the archetype of the pharmacological "double-edged sword." Its therapeutic action stems from its ability to mimic and amplify the effects of the body's primary stress hormone, cortisol. This allows for unparalleled, rapid, and broad-spectrum suppression of inflammatory and immune processes, providing life-saving and symptom-relieving benefits across a vast landscape of diseases. No other class of drugs can so effectively and quickly control the diverse manifestations of inflammation.

However, this very mechanism is also the source of its toxicity. The extensive and severe adverse effect profile is not an off-target effect but rather the predictable consequence of inducing a state of chronic, supraphysiologic hypercortisolism. The clinical challenge, therefore, has always been one of balance: how to leverage the profound anti-inflammatory benefits while mitigating the inevitable harm. The art of corticosteroid therapy lies in using the lowest possible dose for the shortest possible duration, employing local administration routes where feasible, and maintaining vigilant monitoring for the onset of metabolic, musculoskeletal, and other complications. The historical arc of Cortisone, from its initial reception as a "wonder drug" to its current status as a medication used with significant caution and respect for its risks, reflects the maturation of clinical pharmacology itself.

Future Directions and Emerging Research

While the primary clinical and research focus for corticosteroids has been on refining their use in inflammation and immunology, recent discoveries suggest that the biological activities of the steroid nucleus may be far broader than previously understood. A striking example is the finding that Cortisone can function as a potent germinant for the spores of certain bacteria, such as Clostridium sordellii.[4]

This non-canonical biological activity is entirely independent of the glucocorticoid receptor and the classic anti-inflammatory pathways. It implies that the cortisone molecule can interact with specific receptors or pathways within the microbial world, a domain of steroid biology that has been largely unexplored. This discovery opens a potential paradigm shift for the application of steroid-based molecules. Research cited alongside this finding suggests a novel therapeutic strategy: using a germinant to trigger the premature germination of dormant, highly resistant bacterial spores, thereby rendering them susceptible to conventional antibiotics.[4] This could provide a new approach to eradicating persistent infections caused by spore-forming pathogens like Clostridioides difficile.

This line of research suggests that a class of drugs defined for over 70 years by its ability to suppress the host immune system could be repurposed as the basis for developing pro-infective (germinant) adjuvants designed to enhance anti-infective therapies. This counterintuitive potential illustrates that even one of the oldest and most well-studied molecules in the pharmacopeia may hold surprising new roles, ensuring that the story of Cortisone is far from over.

Works cited

1. Cortisone: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed October 18, 2025, https://go.drugbank.com/drugs/DB14681
2. Cortisone | C21H28O5 | CID 222786 - PubChem, accessed October 18, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Cortisone
3. Cortisone (17α-hydroxy-11-Dehydrocorticosterone, Kendall's Compound E, 4-Pregnene-17α,21-diol-3,11,20-trione, Reichstein's Substance Fa, CAS Number: 53-06-5) | Cayman Chemical, accessed October 18, 2025, https://www.caymanchem.com/product/30763/cortisone
4. Cortisone 53-06-5 | Tokyo Chemical Industry Co., Ltd.(APAC), accessed October 18, 2025, https://www.tcichemicals.com/OP/en/p/C1317
5. Cortisone | CAS 53-06-5 - LGC Standards, accessed October 18, 2025, https://www.lgcstandards.com/US/en/Cortisone/p/DRE-C11705400
6. Cortisone - CAS Common Chemistry, accessed October 18, 2025, https://commonchemistry.cas.org/detail?cas_rn=53-06-5&search=53-06-5
7. Everything You Need to Know About Corticosteroids - Healthline, accessed October 18, 2025, https://www.healthline.com/health/corticosteroids-what-are-they
8. Cortisone - Wikipedia, accessed October 18, 2025, https://en.wikipedia.org/wiki/Cortisone
9. Pharmacologic Characteristics of Corticosteroids - :: Journal of Neurocritical Care, accessed October 18, 2025, https://www.e-jnc.org/upload/pdf/jnc-170035.pdf
10. 3D structure for Cortisone (DB14681) | DrugBank Online, accessed October 18, 2025, https://go.drugbank.com/structures/small_molecule_drugs/DB14681
11. LC-MS/MS Spectrum - LC-ESI-ITFT , positive (DB14681) | DrugBank, accessed October 18, 2025, https://go.drugbank.com/spectra/ms_ms/449079
12. CORTISONE(53-06-5) MS spectrum - ChemicalBook, accessed October 18, 2025, https://www.chemicalbook.com/SpectrumEN_53-06-5_MS.htm
13. Diamonds are forever: the cortisone legacy in: Journal of ..., accessed October 18, 2025, https://joe.bioscientifica.com/view/journals/joe/195/1/1940001.xml
14. The discovery of cortisone: a personal memory - PMC, accessed October 18, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC1113923/
15. Pharmacology of corticosteroids - Deranged Physiology, accessed October 18, 2025, https://derangedphysiology.com/main/cicm-primary-exam/endocrine-system/Chapter-221/pharmacology-corticosteroids
16. Cortisone acetate: Uses, Interactions, Mechanism of Action ..., accessed October 18, 2025, https://go.drugbank.com/drugs/DB01380
17. Corticosteroids - StatPearls - NCBI Bookshelf, accessed October 18, 2025, https://www.ncbi.nlm.nih.gov/books/NBK554612/
18. go.drugbank.com, accessed October 18, 2025, https://go.drugbank.com/drugs/DB01380#:~:text=Corticosteroids%20bind%20to%20the%20glucocorticoid,and%20promoting%20anti%2Dinflammatory%20signals.&text=The%20duration%20of%20action%20is,is%20generally%20given%20once%20daily.
19. Corticosteroid Medication - Physiopedia, accessed October 18, 2025, https://www.physio-pedia.com/Corticosteroid_Medication
20. Glucocorticoids | Anti-Inflammation - Mechanism of Action - YouTube, accessed October 18, 2025, https://www.youtube.com/watch?v=9t4AXDt6yF0
21. Pharm 101: Corticosteroids • LITFL • Top 200 Drugs, accessed October 18, 2025, https://litfl.com/pharm-101-corticosteroids/
22. 04. Oral Corticosteroids | Hospital Handbook, accessed October 18, 2025, https://hospitalhandbook.ucsf.edu/04-oral-corticosteroids/04-oral-corticosteroids
23. Clinical Pharmacokinetics of Prednisone and Prednisolone 001 Biogen Ex 2030-p. 1 Pfizer v Biogen IPR2017-01166, accessed October 18, 2025, https://ptacts.uspto.gov/ptacts/public-informations/petitions/1486194/download-documents?artifactId=5PhagMgYPR83KaAqI3U5kc92X7RD4Uq_SrqkOwVyVX85z5Cum6XOEms
24. Pharmacokinetics and Pharmacodynamics of Systemic Corticosteroids in Autoimmune and Inflammatory Diseases: A Review of Current Evidence - PMC, accessed October 18, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11450095/
25. Pharmacokinetics of Corticosteroids - Holland-Frei Cancer Medicine ..., accessed October 18, 2025, https://www.ncbi.nlm.nih.gov/books/NBK13300/
26. (cortisone) dosing, indications, interactions, adverse effects, and more, accessed October 18, 2025, https://reference.medscape.com/drug/cortisone-342742
27. HYDROCORTISONE PANPHARMA (Panpharma Australia Pty Ltd ..., accessed October 18, 2025, https://www.tga.gov.au/resources/prescription-medicines-registrations/hydrocortisone-panpharma-panpharma-australia-pty-ltd
28. Corticosteroids (Glucocorticoids): Definition & Side Effects, accessed October 18, 2025, https://my.clevelandclinic.org/health/treatments/corticosteroids-glucocorticoids
29. Corticosteroids (Glucocorticoids): Types, Risks, & Side Effects | Arthritis Foundation, accessed October 18, 2025, https://www.arthritis.org/drug-guide/corticosteroids/corticosteroids
30. Corticosteroids (steroids) | NHS inform, accessed October 18, 2025, https://www.nhsinform.scot/tests-and-treatments/medicines-and-medical-aids/types-of-medicine/corticosteroids-steroids/
31. Steroids - HSE, accessed October 18, 2025, https://www2.hse.ie/medicines/steroids/
32. B-cell Non Hodgkin's Lymphoma Recruiting Phase 1 Trials for Cortisone (DB14681), accessed October 18, 2025, https://go.drugbank.com/indications/DBCOND0072476/clinical_trials/DB14681?phase=1&status=recruiting
33. Hydrolyzed Collagen Peptides Completed Phase Trials for Cortisone (DB14681), accessed October 18, 2025, https://go.drugbank.com/indications/DBCOND0161328/clinical_trials/DB14681?status=completed
34. Cortisone Completed Phase N/A Trials for Partial Tear of Rotator Cuff Treatment - DrugBank, accessed October 18, 2025, https://go.drugbank.com/drugs/DB14681/clinical_trials?conditions=DBCOND0074798&purpose=treatment&status=completed
35. FDA Drug Safety Communication for Corticosteroid, accessed October 18, 2025, https://www.fda.gov/media/88483/download
36. Steroid injections - HSE, accessed October 18, 2025, https://www2.hse.ie/medicines/steroid-injections/
37. Hydrocortisone: MedlinePlus Drug Information, accessed October 18, 2025, https://medlineplus.gov/druginfo/meds/a682206.html
38. 15-Acute short term effects from corticosteroids - eviQ, accessed October 18, 2025, https://www.eviq.org.au/clinical-resources/side-effect-and-toxicity-management/prophylaxis-and-treatment/15-acute-short-term-effects-from-corticosteroids
39. Prednisone and other corticosteroids: Balance the risks and benefits - Mayo Clinic, accessed October 18, 2025, https://www.mayoclinic.org/tests-procedures/cortisone-shots/in-depth/steroids/art-20045692
40. Side effects of prednisolone tablets and liquid - NHS, accessed October 18, 2025, https://www.nhs.uk/medicines/prednisolone/side-effects-of-prednisolone-tablets-and-liquid/
41. Short-Term Systemic Corticosteroids: Appropriate Use in Primary ..., accessed October 18, 2025, https://www.aafp.org/pubs/afp/issues/2020/0115/p89.html
42. Understanding Oral Corticosteroid Side Effects - Allergy & Asthma Network, accessed October 18, 2025, https://allergyasthmanetwork.org/ocs-oral-corticosteroids/understanding-ocs-side-effects/
43. www.ncbi.nlm.nih.gov, accessed October 18, 2025, https://www.ncbi.nlm.nih.gov/books/NBK531462/#:~:text=%5B13%5D%20These%20adverse%20effects%20include,of%20hair%2C%20and%20perioral%20dermatitis.&text=Glucocorticoids%20increase%20the%20risk%20of,ulcer%20formation%2C%20and%20GI%20bleeding.
44. Corticosteroid - Wikipedia, accessed October 18, 2025, https://en.wikipedia.org/wiki/Corticosteroid
45. Prednisone (oral route) - Side effects & dosage - Mayo Clinic, accessed October 18, 2025, https://www.mayoclinic.org/drugs-supplements/prednisone-oral-route/description/drg-20075269
46. www.ncbi.nlm.nih.gov, accessed October 18, 2025, https://www.ncbi.nlm.nih.gov/books/NBK554612/#:~:text=Contraindications%20to%20corticosteroids%20include%20hypersensitivity,mellitus%2C%20glaucoma%2C%20joint%20infection%2C
47. Local and Systemic Side Effects of Corticosteroid Injections for ..., accessed October 18, 2025, https://ajronline.org/doi/10.2214/AJR.23.30458
48. Steroids and Corticosteroids | PM&R KnowledgeNow - AAPM&R, accessed October 18, 2025, https://now.aapmr.org/steroids-and-corticosteroids/
49. Hydrocortisone (injection route) - Side effects & uses - Mayo Clinic, accessed October 18, 2025, https://www.mayoclinic.org/drugs-supplements/hydrocortisone-injection-route/description/drg-20406236
50. Home : reference website about corticosteroids - Cortisone Info, accessed October 18, 2025, https://cortisone-info.com/en/general-information/drug-interactions/
51. Prednisone: Uses & Side Effects - Cleveland Clinic, accessed October 18, 2025, https://my.clevelandclinic.org/health/drugs/20469-prednisone-tablets
52. Determination That CORTONE (Cortisone Acetate) Tablets and Other Drug Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness - Federal Register, accessed October 18, 2025, https://www.federalregister.gov/documents/2017/09/15/2017-19611/determination-that-cortone-cortisone-acetate-tablets-and-other-drug-products-were-not-withdrawn-from
53. cortisone | healthdirect, accessed October 18, 2025, https://www.healthdirect.gov.au/medicines/medicinal-product/aht,D003348/cortisone
54. CORTISONE - Pharmaceutical Benefits Scheme (PBS), accessed October 18, 2025, https://www.pbs.gov.au/medicine/item/1246n-1247p
55. CIPLA HYDROCORTISONE, CORTI-H, CORTICIP, HYDROCIP (Cipla Australia Pty Ltd), accessed October 18, 2025, https://www.tga.gov.au/resources/prescription-medicines-registrations/cipla-hydrocortisone-corti-h-corticip-hydrocip-cipla-australia-pty-ltd
56. HYDROCORTISONE ... - Pharmaceutical Benefits Scheme (PBS), accessed October 18, 2025, https://www.pbs.gov.au/medicine/item/1501b-1510l-1511m-3096y-3470p-3471q-5118j-5119k
57. APOHEALTH Hydrocortisone 1% Cream - NPS MedicineWise, accessed October 18, 2025, https://www.nps.org.au/medicine-finder/apohealth-hydrocortisone-1-cream
58. FDA Circular No.2024-002 || Recall and Withdrawal of the Classification and Registration of Topical Corticosteroids as Over-the-Counter and Household Remedy Drug, accessed October 18, 2025, https://www.fda.gov.ph/fda-circular-no-2024-002-recall-and-withdrawal-of-the-classification-and-registration-of-topical-corticosteroids-as-over-the-counter-and-household-remedy-drug/
59. Oral Corticosteroid Medications | AAAAI, accessed October 18, 2025, https://www.aaaai.org/tools-for-the-public/drug-guide/oral-corticosteroid-medications
60. Hydrocortisone (topical application route) - Side effects & dosage - Mayo Clinic, accessed October 18, 2025, https://www.mayoclinic.org/drugs-supplements/hydrocortisone-topical-application-route/description/drg-20073814
61. Popular Corticosteroids List, Drug Prices and Medication Information - GoodRx, accessed October 18, 2025, https://www.goodrx.com/classes/corticosteroids
62. hydrocortisone - medicine shortage information - Therapeutic Goods Administration (TGA), accessed October 18, 2025, https://apps.tga.gov.au/Prod/msi/Search/Details/hydrocortisone
63. Prednisolone tablets and liquid: steroid medicine - NHS, accessed October 18, 2025, https://www.nhs.uk/medicines/prednisolone/
64. Glucocorticoids (Prednisone, Depo-Medrol®, Aristospan®, Kenalog ..., accessed October 18, 2025, https://creakyjoints.org.au/education/arthritis_treatment_options/glucocorticoids/
65. Predsolone - Prednisolone - NPS MedicineWise, accessed October 18, 2025, https://www.nps.org.au/medicine-finder/predsolone-tablets